The Labcorp OnDemand Colon Cancer Test. At-home screening with lab-level analytics

Labcorp OnDemand Colon Cancer Test brings CLIA-certified lab screening for colorectal cancer risk into the living room with a mailed stool sample kit and online results. Anyone holding Labcorp stock (NYSE: LH, ISIN US50540R4092) should know this product.

By Daniel Foster, ad hoc news Classics & Longsellers Desk. Reviewed July 05, 2026, 1:38 AM ET. Details in the imprint.

Labcorp OnDemand Colon Cancer Test sits quietly on the kitchen counter, a compact cardboard kit with a bright blue label and a simple set of instructions tucked inside. You notice the faint antiseptic smell when you crack open the inner vial and unfold the collection paper. It’s an at-home stool test designed to feed your sample straight into Labcorp’s national lab network without ever stepping into a doctor’s office.

What the Labcorp kit actually does

The Labcorp OnDemand Colon Cancer Test is an at-home, physician-ordered stool test that screens for blood in the stool and other markers associated with colorectal cancer risk, using Labcorp’s CLIA-certified laboratories in the United States. Official product overview After ordering the kit online, consumers receive a box by mail with a collection device, sample vial with preservative solution, and a prepaid return mailer to send the specimen back to Labcorp.

Labcorp describes OnDemand as a platform that offers a broad range of physician-ordered tests, including colon cancer screening, through an online experience that ties directly into its diagnostic lab infrastructure. OnDemand test portfolio Once the stool sample for the colon cancer test arrives at Labcorp, the company processes it in accredited labs, analyzes results, and makes them available through a secure online portal and, in many cases, with physician follow-up for abnormal findings.

How the at-home process works

From a user’s point of view, the process starts on Labcorp’s OnDemand website, where the Colon Cancer Test is listed with eligibility criteria and a short description of what the stool test detects. Test catalog and pricing You complete a questionnaire, the order is reviewed by a licensed physician, and the kit ships to your home, usually within a few business days in the continental United States.

Inside the kit, there is a paper collection aid that sits over the toilet bowl and a small plastic sampling wand attached to the vial cap, designed to collect a portion of stool without direct hand contact. OnDemand FAQs The preservative solution inside the vial has a sharp, slightly chemical scent when opened, a reminder that the sample is being prepped for transport and testing rather than simple disposal.

Clinical backdrop and screening guidelines

The Labcorp OnDemand Colon Cancer Test fits into a broader public health push to expand colorectal cancer screening, especially for people who may delay colonoscopy due to access barriers, cost, or discomfort. CDC screening overview The U.S. Preventive Services Task Force recommends regular screening for most adults starting at age 45, using stool-based tests, colonoscopy, or other approved modalities.

Stool tests like Labcorp’s at-home offering typically check for occult blood and sometimes additional biomarkers linked to colorectal neoplasia, making them a noninvasive alternative that can be done without sedation or bowel prep. Labcorp highlights the physician oversight component and follow-up protocols when positive results are detected, directing patients toward colonoscopy or further evaluation. Occult blood testing background

Pricing, insurance, and U.S. availability

Labcorp lists OnDemand test pricing directly on its consumer site, and the Colon Cancer Test is marketed as available in most U.S. states subject to regulatory approvals and physician ordering rules. Pricing and billing information In practice, the stool test often costs less than a diagnostic colonoscopy and may be paid out of pocket when insurance coverage is unclear, though coverage varies by plan and employer.

Labcorp positions its OnDemand line as a complement, not a replacement, for traditional physician visits and colonoscopy referrals, underscoring that abnormal results should trigger further evaluation. In conversations with investors, Labcorp CEO Adam Schechter has repeatedly pointed to consumer-centered offerings like OnDemand as a way to diversify revenue and tap into demand for convenient diagnostics. Investor presentations and remarks

Labcorp context and stock

Labcorp is one of the largest clinical laboratory networks in the United States, running millions of diagnostic tests each year through hospital, physician, and employer channels as well as its growing OnDemand platform. For retail investors, the Colon Cancer Test is one small but visible piece of Labcorp’s effort to meet consumers where they are and turn preventive screening into recurring diagnostic revenue over time.

Labcorp stock (NYSE: LH, ISIN US50540R4092) is listed in New York, and its overall performance reflects trends in diagnostic testing volumes, managed care partnerships, and uptake of at-home services like OnDemand rather than sales of individual kits.

Labcorp OnDemand Colon Cancer Test at a glance

• Product: Labcorp OnDemand Colon Cancer Test
• Manufacturer: Laboratory Corporation of America Holdings
• Category: Classics & Longsellers diagnostic test
• Launch: Offered as part of Labcorp OnDemand home test portfolio in the U.S. in the early 2020s
• MSRP / Price: Listed as a consumer-pay stool test on Labcorp’s OnDemand site (exact USD pricing subject to updates and insurance)
• Availability: Most U.S. states via online ordering and mail-in kit, subject to physician review and state regulations
• Target audience: Adults seeking noninvasive colorectal cancer risk screening under medical oversight, particularly those reluctant to schedule colonoscopy
• Standout / USP: At-home stool collection with direct integration into Labcorp’s CLIA-certified lab network and physician-supported result delivery

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.